Feature: Part 2: CME # 115 — June 2003 Advances and Challenges in Melanoma - By Nancy E. Thomas, M.D., Ph.D., David W. Ollila, M.D., and Thomas Hensing, M.D. Clinical Diagnosis, Staging, Sentinel Lymph Node Biopsy and Medical Treatment Options Unsuspected Drainage Patterns With widespread use of lymphatic mapping and sentinel lymphadenectomy, more precise mapping of the drainage of a primary cutaneous melanoma has developed. With this precision, several previously held beliefs regarding lymphatic drainage have been dispelled. The most notable flaw in our previous understanding of lymphatic mapping was the concept of “Sappey’s lines” around the trunk.80 Sappey believed lymphatic drainage never crossed midline and that there was an ambiguous zone within 5 cm of the umbilicus transversely. Clearly with the further delineation of lymphatic mapping, it’s clear that a patient’s lymphatic drainage pattern can cross midline and that zones of ambiguity extend much greater than just 5 cm within the umbilicus.87,82 Furthermore, areas that are not typically felt to be nodal-bearing regions have become very important in the accurate lymphatic mapping, including the intermuscular space83 just lateral to the scapula and the epitrochlear and popliteal nodes.84 These aberrant drainage patterns illustrate the complexity of the procedure as well as the importance of coordination between the nuclear medicine physicians and the surgeon. Side Effects of LM/SL The injections of the technetium-99m sulfur colloid, while uncomfortable to the patient, have no real side effects. The side effects of the injected mapping agents are predominantly due to the isosulfan blue dye. Following the intradermal injection of the isosulfan blue dye, some patients have a false drop in the oxygen saturation on the pulse oximeter. This doesn’t represent a true hypoxemia. However, some patients can have anaphylactic-type reaction to the isosulfan blue dye. This can range from hypoxemia with bronchospasm to hypotension to blue urticaria.85 These anaphylactic-type reactions are usually easily supported with increasing FIO2, increasing positive and expiratory pressure, intravenous diphenhydramine and intravenous methylprednisolone. The Phase III trials for isosulfan blue dye only showed a 0.9% adverse effect incidence (5/543 patients) and all of these reactions were minor.86 Other complications associated with LM/SL involve local wound problems. These include cellulitis and/or infections that occur in 2% to 3% of patients. These are most commonly seen in the inguinal region lymph nodes. About 5% to 7% of patients develop seromas at the SN excision site. Most seromas resolve with expectant management; however, some may require percutaneous aspiration. Paraesthesias secondary to injury to one of the local cutaneous sensory nerves can occur. The true incidence of lymphedema following this procedure is not known. It’s being prospectively studied in a breast cancer trial by the American College of Surgeons Oncology Group Trial. Lymphadenectomy Trial Accrual to the Phase III randomized trial (Multicenter Selective Lymphadenectomy Trial, D.L. Morton, Principal Investigator) randomizing cutaneous melanoma patients to wide local excision with or without lymphatic mapping and sentinel lymphadenectomy is complete, and we await data analysis, but in the interim, a couple of things are clear. First, there is no role for elective lymph node dissection in patients with cutaneous melanoma. Second, lymphatic mapping and sentinel lymphadenectomy is a complex process that requires the coordination and expertise of three separate disciplines — nuclear medicine, surgery and pathology. All three disciplines are vital to ensure the high accuracy rates (99%) associated with this procedure. Medical Treatment Options • Adjuvant Therapy of High-risk Disease. Interferon alpha is the only approved therapy for patients with high-risk melanoma that has been surgically resected. However, the use of interferon in the adjuvant setting remains controversial. There have been several randomized trials that have reported significant improvements in disease-free survival when patients are treated with interferon compared to observation, but this hasn’t consistently translated into an improvement in survival.88-90 To date, there have been two randomized trials that have reported a significant beneficial impact on overall survival with interferon alfa after definitive surgery.91,92 The first trial, which led to the FDA approval of interferon, randomized patients with deep melanomas (greater than 4.0 mm) or with positive regional lymph nodes after surgery to 1 year of interferon or observation.91 In this trial, interferon was administered intravenously for 1 month, followed by subcutaneous administration three times every week for 48 weeks. The 5-year survival rate on the treatment arm was 46%, compared to 37% for observation (p = 0.0237). In the second trial, this dose and schedule of interferon was compared to a melanoma vaccine.92 This trial was stopped early after an interim analysis indicated a significant survival benefit favoring the interferon arm. The toxicity of interferon can be significant. In the initial ECOG trial, a dose delay or reduction was required for toxicity at least once in 50% of the patients during the first month of intravenous interferon, and 48% of the patients during the 48 weeks of subcutaneous treatment.91 The most common toxicities included constitutional symptoms, myelosuppression, elevated liver enzymes and neurological toxicity. Most toxicities were reversible, and after 4 months of therapy, most patients remaining on study were able to complete therapy. Patients with deep primary melanomas (>4.0 mm) or stage III disease should be considered for adjuvant therapy after definitive surgery. Other high-risk patients, including those with intermediate-thickness melanomas (1.0 mm to 4.0 mm) that are ulcerated or those patients who have had resection of distant metastases (stage IV), should be considered for adjuvant therapy. Despite its limitations, Interferon alpha remains the only reasonable option outside the setting of a clinical trial for these high-risk patients. There are several additional strategies currently being investigated in the adjuvant setting, including vaccine and other immunotherapy-based approaches. Although these strategies remain experimental, consider patients at high risk for relapse for clinical trials. • Systemic Therapy for Metastatic Disease. Once melanoma has spread beyond the regional nodal basin, the overall prognosis is quite poor and less than 5% of patients will be long-term survivors. Currently, cytotoxic chemotherapy has a limited role in the management of patients with disseminated melanoma. Dacarbazine (DTIC) is the most common chemotherapeutic agent that has been studied in this disease. Radiographic response rates range from 15% to 20% as a single agent.93 The majority of responses with any chemotherapeutic regimen is generally partial and lasts less than 3 to 4 months, with complete responses occurring in less than 5% of patients.94 Although DTIC-based combination regimens are associated with higher overall response rates, they have not improved survival when compared to single-agent DTIC in randomized trials.95 Like interferon, interleukin-2 (IL-2) is a biological agent with activity in advanced melanoma. IL-2 is a potent T-cell growth factor and immunomodulator. Based on activity in pre-clinical models, IL-2 was initially tested in patients in a high-dose schedule that required in-patient administration.96 In a recent update of the database generated from trials conducted by the National Cancer Institute and Cytokine Working Group, treatment with IL-2 resulted in an overall response rate of 16%, with 6% of patients achieving a complete remission.97 In contrast to the experience with chemotherapy, the responses were more prolonged, with median response duration of 5.9 months for the partial responders, and a median response duration that had not been reached for those patients who had achieved a complete response. There were no relapses in patients whose complete response lasted more than 30 months, suggesting that a small percentage of patients may be cured from their disease. However, also like interferon, the toxicity with IL-2 is significant and only a limited number of patients will be candidates for this therapy. Combinations of chemotherapy and biologic agents, including interferon and IL-2, referred to as biochemotherapy, have shown promising results in initial testing, and randomized trials studying these regimens are ongoing.98 Still Work to be Done Ultimately, there remains a need to develop novel treatment strategies for patients with metastatic melanoma, and most patients with metastatic melanoma should also be considered for clinical trials. References: 1. American Cancer Society 2003, Facts & Figures, www.cancer.org 2. Richert SM, D’Amico F, Rhodes AR. Cutaneous melanoma: patient surveillance and tumor progression (abstract). J Invest Dermatol. 1997;108:36 3. Marghoob AA, Slade J, Kopf AW, Salopek TG, Rigel DS. Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study. British J Dermatol. 1996;135:704-711. 4. Masri GD, Clark WH, Guerry IV, D, Halpern A, Thompson J, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Amer Acad Dermatol. 1990;22:1043-1048. 5. Koh HK, Geller AC, Miller DR, Lew RA. The early detection of and screening for melanoma. Cancer 75:674, 1995. 6. NIH Consensus Conference. Diagnosis and treatment of early melanoma. JAMA. 268:1314,1992. 7. Berwick M. Epidemiology: Current Trends, Risk Factors and Environmental Concerns in: Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds), Cutaneous Melanoma, 3rd Ed. Quality Medical Publishing, Inc, St. Louis, Missouri 1998; 551. 8. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin. 1985;35(3):130-151. 9. Thomas L, Tranchand P, Berard F, Secchi T, Colin C, Moulin G. Semiological Value of ABCDE Criteria in the Diagnosis of Cutaneous Pigmented Tumors. Dermatology. 1998;197:11-17. 10. Carli P, Borgognoni L, Reali UM, Giannotti B. Clinico-pathological features of small diameter malignant melanoma. Eur J Dermatol. 1994;4:440-442. 11. Higgins EM, Hall P, Todd P, Murthi R, Du Vivier AWP. The application of the seven-point check-list in the assessment of benign pigmented lesions. Clin and Exp Dermatol. 1992;17:313-315. 12. Moynihan GD. The 3 Cs of melanoma: Time for a change? J Am Acad Dermatol. 1994;30:510-511. 13. Tierstan AD, Grin CM, Kopf AW, Gottlieb J, Bart RS, Rigel DS, Friedman RJ, Levenstein MJ. Prospective Follow-up for Malignant Melanoma in Patients with Atypical-Mole (Dysplastic-Nevus) Syndrome. J Surg Oncol. 1991;17:44-48. 14. Rivers JH, Kopf AW, Vinokur AF, Rigel, DS, Friedman RJ, Heilman ER, et al. Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi. Cancer 1990;65:1232-6. 15. Halpern AC, Guerry D, Elder DE, Trock B, Synnestvedt M. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993;100:346-9. 16. Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. MJA 1997;167:191-4. 17. Gritchnik, JM. CD-ROM Total Body Images for Clinical Follow-up of Patients at high Risk of Primary Cutaneous Melanoma. The Melanoma Letter. 1998;16(2)3-4. 18. Ringel DS. Epiluminescence microscopy in clinical diagnosis of pigmented skin lesions? Lancet. 1997;349:1566-1567. 19. Binder M, Puespoeck SM, Steiner A, Kittler H, Muellner M, Wolff K, et al. Epiluminescence microscopy of small pigmented skin lesions: short term formal training improves the diagnostic performance of dermatologists. J Am Acad Dermatol. 1997;36:197-202. 20. Lorentzen H, Weismann k, Petersen CS, Larsen FG, Secher L, Skodt V. Clinical and Dermatoscopic Diagnosis of Malignant Melanoma. Acta Derm Venereol. 1999;79:301-304. 21. Bafounta, M, Beauchet A, Aegerter P, Saiag P. Is Dermoscopy (Epiluminescence Microscopy) Useful for the Diagnosis of Melanoma? Arch Dermatol. 2001;137:1343-1350. 22. Stolz W, Riemann A, Cognetta AB, Pillet I, Abmayr W, Holzel D, Bilek P, Nachbar F, Lanthaler M, Braun-Falco O. ABCD rule of dermatoscopy: a new practical method for early regognition of malignant melanoma. Eur J Dermatol. 1994;4:521-527. 23. Nilles M, Boedeker RH, Schill WB. Surface microscopy of naevi and melanomas-clues to melanoma. Br J Dermatol. 1994;130:349-355. 24. Menzies SW, Ingvar C, McCarty WH. A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma. Melanoma Res. 1996;6:55-62. 25. Dal Pozzo V, Roscett E, Benelli C. The seven features for melanoma (7FFM) a new dermoscopic algorithm for the diagnosis of melanoma. Eur J Dermatol. 1999;9:303-308. 26. Argenziano G, Fabbroncini G, Carli P, De Giogi V, Sammarco E, Delfino M. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Arch Dermatol. 1998;134:1563-1570. 27. Benelli C, Roscetti E, Dal Pozzo V. The dermoscopic (7FFM) versus the clinical (ABCDE) diagnosis of small diameter melanoma. Eur J Dermatol. 2000;10:282-287. 28. Kittler, H., Seltenheim M, Dawid M, Pehamberger H, Wolff K, Binder M. Morphologic changes of pigmented skin lesions: A useful extension of the ABCD rule for dermatoscopy. J Am Acad Dermatol. 1999;40:558-562. 29. Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: Patterns of modifications observed in early melanoma, atypical nevi and common nevi. J Am Acad Dermatol. 2000;43(3):467-475. 30. Benelli C, Roscetti E, Dal Pozzo V, Gasparini G, Cavichini S. The dermoscopic versus the clinical diagnosis of melanoma. Eur J Dermatol. 1999;9:470-6. 31. Rosado B, Menzies S, Harbauer A, Pehamberger H, Wolff K, Binder M, Kittler H. Accuracy of Computer Diagnosis of Melanoma. Arch Dermatol. 2003;139:361-367. 32. Binder M, Kittler H, Seeber A, Steiner A, Pehamberger H, Wolff K: Epiluminescence microscopy-based classification of pigmented skin lesions using computerized image analysis and an artificial neural network. Melanoma Res. 1998;8:261-266. 33. Menzies SW, Bischof LM, Peden G, Talbot HG, Gutenev A, Thompson RL, McNamara KW, Burlutski G, McCarthy WH, Skladnev. Automated instrumentation for the diagnosis of invasive melanoma: image analysis of oil epiluminescence microscopy. In: Altmeyer P, Hoffmann K, Stucker M (Eds) Skin cancer and UV radiation. Springer-Verlag, Berlin 1997. 34. Elbaum M., Kopf AW, Rabinovitz HS, Langley RGB, Kamino H, Mihm MC, Sober AJ, Peck GL, Bogdan A, Gutkowicz-Krusin D, Geenebaum M, Keem S, Oliviero M, Wang S. Automatic defferentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: A feasibility study. J Amer Acad Dermatol. 2001;44:207-18. 35. Fleming MG, Steger C, Cognetta AB, Zhang J. Analysis of the network pattern in dermatoscopic images. Skin Research and Technology. 1999;5:42-48. 36. Seinenari S, Pellacani G, Giannetti A. Digital videomicroscopy and image analysis with automatic classification for detection of thin melanomas. Melanoma Res. 1999;9:163-171. 37. Andreassi L, Perotti R, Rubegni P, Burroni M, Cevenini G, Biagioli M, Taddeucci P, Dell’Eva G, Barbini P. Digital dermoscopy analysis for the differentiation of atypical nevi and early melanoma. Arch Dermatol. 1999;135:1459-1465. 38. Moncrieff M, Cotton S, Claridges E, Hall P. Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. Brit J Dermatol. 2002;146:448-457. 39. Langley, RGB, Rajadhyaksha M, Dwyer PJ, Sober AJ, Flotte TJ, Anderson RR. Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivo. J Amer Acad Dermatol. 2001;45:365-76. 40.Garrison M, Nathanson L: Prognosis and staging in melanoma. Seminars in Oncology. 1996; 23:725-733. 41. Iftikhar A: Malignant melanoma: Prognostic indicators. Mayo Clinic Proceedings. 1997; 72(4):356-361. 42. Garbe C, Buttner P, Bertz J: Primary cutaneous melanoma, identification of prognostic groups and estimation of individual prognosis for 5,093 patients. Cancer. 1995; 75:2484. 43. Karakousis C, Emrich L, Rao U: Tumor thickness and prognosis in clinical stage I malignant melanoma. Cancer. 1989; 64:1432. 44. Morton D, Davtyan D, Wanek L: Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark Level and Breslow thickness. Cancer. 1993; 71:3737. 45. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Annals of Surgery. 1970; 172:902-908. 46. Clark W, L F, Bernardino E, et al: The histogenesis and biologic behavior of primary malignant melanomas of the skin. Cancer Res. 1969; 29:705-726. 47. Balch CM, Soong S-J, Gershenwald JE, et al: Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2001; 19:3622-3634. 48. Balch C, Murad T, Soong S-J: A multifactorial analysis of melanoma. Prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Annals of Surgery. 1978; 188:732. 49. Balch C, Soong S, Shaw H: An analysis of prognostic factors in 8,500 patients with cutaneous melanoma, in Balch C, Houghton A, Milton G (eds): Cutaneous Melanoma. Philadelphia, Lippincott, 1992, pp. 165. 50. Kemeny M, Busch E, Stewart A, et al: Superior survival of young women with malignant melanoma. Am J Surg. 1998; 175. 51. Balch CM, Buzaid AC, Soong S-J, et al: Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001; 19:3635-3648. 52. Balch C, Soong S-J, Murad T, et al: A multifactorial analysis of melanoma III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Annals of Surgery. 1981; 193:377-388. 53. Barth A, Wanek L, Morton D: Prognostic factors in 1,512 melanoma patients with distant metastases. Journal of the American College of Surgery. 1995; 181:193. 54. Sirott M, Bajorin D, Wong G, et al: Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis. Cancer. 1993; 72:3091-3098. 55. Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group Trials. J Clin Oncol. 2000; 18. 56. Essner R, Morton D. Elective lymph node dissection. In LeJeune F, Chaudhuri P, Das Gupta T, eds. Malignant melanoma. New York: McGraw-Hill, 1993. pp. 205-214. 57. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Annals of Surgery. 1982; 196(6):677-84. 58. Milton GW, Shaw HM, McCarthy WH, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. British Journal of Surgery. 1982; 69(2):108-11. 59. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. New England Journal of Medicine 1977; 297(12):627-30. 60. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer. 1978; 41(3):948-56. 61. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Annals of Surgery. 1996; 224(3):255-63; discussion 263-6. 62. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992; 127(4):392-9. 63. Robinson DS, Sample WF, Fee HJ, et al. Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning. Surgical Forum. 1977; 28:147-8. 64. Meyer CM, Lecklitner ML, Logic JR, et al. Technetium-99m sulfur-colloid cutaneous lymphoscintigraphy in the management of truncal melanoma. Radiology. 1979; 131(1):205-9. 65. Sullivan DC, Croker BP, Jr., Harris CC, et al. Lymphoscintigraphy in malignant melanoma: 99mTc antimony sulfur colloid. AJR. American Journal of Roentgenology. 1981; 137(4):847-51. 66. Morton D, Cagle L, Wong J, et al. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure for clinical stage I melanoma. Society of Surgical Oncology. Washington DC, 1990. 67. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977; 39(2):456-66. 68. Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol. 1993; 2(3):137-43. 69. Alex JC, Weaver DL, Fairbank JT, et al. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol. 1993; 2(5):303-8. 70. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Annals of Surgery. 1996; 223(2):217-24. 71. Leong SP, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Archives of Surgery. 1997; 132(6):666-72; discussion 673. 72. Bostick P, Essner R, Sarantou T, et al. Intraoperative lymphatic mapping for early-stage melanoma of the head and neck. American Journal of Surgery. 1997; 174(5):536-9. 73. Pijpers R, Borgstein PJ, Meijer S, et al. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World Journal of Surgery. 1997; 21(8):788-92; discussion 793. 74. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study [see comments]. Am J Surg Pathol. 1988; 12(8):612-8. 75. Gaynor R, Herschman HR, Irie R, et al. S100 protein: a marker for human malignant melanomas? Lancet. 1981; 1(8225):869-71. 76. Kelley M, Ollila D, Morton D. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Seminars in Surgical Oncology. 1998; 14:283-290. 77. Reintgen D. Lymphatic mapping and sentinel node harvest for malignant melanoma. Journal of Surgical Oncology. 1997; 66(4):277-81. 78. Ross MI. Lymphatic mapping and sentinel node biopsy for early stage melanoma: how we do it at the M. D. Anderson Cancer Center. Journal of Surgical Oncology. 1997; 66(4):273-6. 79. Stitzenberg KB, Calvo BF, Iacocca MV, et al. Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer. American Journal of Clinical Pathology. 2002; 117(5):729-37. 80. Sappey M. Injection, préparation et conservation des vaisseaux lymphatiques. Thèse pour le doctorate en médecine, No. 241. Rignoux Imprimeur de la Faculté de Médecine. Paris, 1843. 81. Norman J, Cruse CW, Espinosa C, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. American Journal of Surgery. 1991; 162(5):432-7. 82. Eberbach MA, Wahl RL. Lymphatic anatomy: functional nodal basins. Annals of Plastic Surgery. 1989; 22(1):25-31. 83. Uren RF, Howman-Giles R, Thompson JF, et al. Lymphatic drainage to triangular intermuscular space lymph nodes in melanoma on the back. Journal of Nuclear Medicine. 1996; 37(6):964-6. 84. Uren RF, Howman-Giles RB, Thompson JF. Failure to detect drainage to the popliteal and epitrochlear lymph nodes on cutaneous lymphoscintigraphy in melanoma patients. Journal of Nuclear Medicine. 1998; 39(12):2195. 85. Sadiq TS, Burns WW, 3rd, Taber DJ, et al. Blue urticaria: a previously unreported adverse event associated with isosulfan blue. Archives of Surgery. 2001; 136(12):1433-5. 86. Hirsch JI, Tisnado J, Cho SR, Beachley MC. Use of isosulfan blue for identification of lymphatic vessels: experimental and clinical evaluation. AJR. American Journal of Roentgenology. 1982; 139(6):1061-4. 87. Ollila D, Stitzenberg K, Hensing T, Thomas N. Lymphatic mapping and sentinel lymphadenectomy should be offered to all patients with thin melanoma (£1.0mm). Society of Surgical Oncology’s 56th Annual Cancer Symposium. Los Angeles, CA, 2003. 88. Creagan E, Dalton R, Ahmann D, et al: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995; 13:2776-2783. 89. Grob J, Dreno B, de la Salmoniere P, et al: Randomised trial of interferon-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet. 1998; 351:1905-1910. 90. Pehamberger H, Soyer H, Steiner A, et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998; 16:1425-1429. 91. Kirkwood J, Strawderman M, Ernstoff M, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14:7-17. 92. Kirkwood J, Ibrahim J, Sosman J, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB/III melanoma: Results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol. 2001; 19:2370-2380. 93. Carbone P, Costello W: Eastern Cooperative Oncology Group Studies with DTIC. Cancer Treat Rep. 1976; 60:193-198. 94. Ahmann D, Creagan E, Hahn R, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer. 1989; 63:224-227. 95. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. J Clin Oncol. 1999; 17:2745-. 96. Rosenberg S, Yang J, Topalian S, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 1994; 271:907-913. 97. Atkins MB, Lotze MT, Dutcher JP, et al: High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. J Clin Oncol. 1999; 17:2105-. 98. Legha S, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha and interleukin-2 for patients with metastatic melanoma. Journal of Clinical Oncology. 1998; 16:1752-1759. Skin & Aging - ISSN: 1096-0120 - Volume 11 - Issue 06 - June 2003 - Pages: 47 - 57